FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer
Read More
News
All
- Fog In The News
- Press Releases
- Publications
Mirror-image ligand discovery enabled by single-shot fast-flow synthesis of D-proteins
Nature Communications
Read More
FogPharma Announces $145 Million Financing to Support Ongoing Clinical Development of FOG-001 and Accelerate Helicon Peptide Portfolio
Read More
FogPharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Read More
Recognition and reprogramming of E3 ubiquitin ligase surfaces by α-helical peptides
Nature Communications
Read More
For biotech entrepreneur Greg Verdine, opportunity just kept knocking
Read More
Fierce Biotech Names FogPharma a “Fierce 15” Biotech Company of 2023
Read More
Introducing Fierce Biotech’s 2023 Fierce 15
Read More
Nature Reviews Drug Discovery: The case for cell-penetrating peptides
Read More
Endpoints: Escaping an improbable upbringing, Greg Verdine places his biggest career bets in drugging the ‘undruggable’
Read More
FogPharma Announces First Patient Dosed in Phase 1/2 Clinical Trial of First-in-class TCF-blocking β-catenin Inhibitor, FOG-001, in Advanced Solid Tumors
Read More
Mathai Mammen, M.D., Ph.D., to Join FogPharma as Chairman, President and Chief Executive Officer
Read More
De Novo Mapping of α-helix Recognition Sites on Protein Surfaces Using Unbiased Libraries
PNAS
Read More
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Read More
Insider: A former Harvard chemist just raised $178 million for a biotech startup that plans to treat previously untreatable cancers
Read More
PharmaVOICE 100: WeiQing Zhou
Read More
FierceBiotech: Biopharma begins to hand AI the keys to the research car
Read More
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
Read More
FogPharma Expands Executive Leadership Team
Read More
Endpoints: Harvard’s Gregory Verdine has big ambitions for his miniprotein ‘braces’ — and now $107M to guide them to the clinic
Read More
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Read More
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
Read More
FogPharma Appoints Dr. Barbara Weber to its Board of Directors
Read More
FierceBiotech: FogPharma collects $66M to advance cell-penetrating cancer inhibitor
Read More
Endpoints: His way: Greg Verdine is building a new kind of drug, with backing from a different kind of investor
Read More
FogPharma Secures $66 Million Series B Financing
Read More
Exceptionally high-affinity Ras binders that remodel its effector domain
Journal of Biological Chemistry
Read More
An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides
Journal of the American Chemical Society
Read More